Product
Olaptesed pegol
Aliases
NOX-A12
Name
Olaptesed pegol
2 clinical trials
1 drug
2 indications
Indication
Pancreatic CancerIndication
GlioblastomaDrug
olaptesed pegolClinical trial
An Open-label Phase 2 Study of Olaptesed Pegol (NOX-A12) Combined With Pembrolizumab and Nanoliposomal Irinotecan/5-FU/Leucovorin or Gemcitabine/Nab-paclitaxel in Microsatellite-stable Metastatic Pancreatic Cancer PatientsStatus: Not yet recruiting, Estimated PCD: 2026-10-01
Clinical trial
Single-arm Dose-escalation Phase 1/2 Study of Olaptesed Pegol (NOX-A12) in Combination With Irradiation in Inoperable or Partially Resected First-line Glioblastoma Patients With Unmethylated MGMT Promoter With a 3-arm Expansion Group Including Fully Resected Patients and Combination With Bevacizumab or PembrolizumabStatus: Active (not recruiting), Estimated PCD: 2024-12-01